Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. (Q38154151)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 October 2013

Language	Label	Description	Also known as
English	Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.	scientific article published on 21 October 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141774%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141774%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

based on heuristic

inferred from title

Kingston H Mills

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141774%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

A Q Butt

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141774%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

0 references

publication date

21 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141774%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141774%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

33

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141774%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

38

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141774%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

4623-4631

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141774%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Adaptive immunity maintains occult cancer in an equilibrium state

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Targeting regulatory T cells in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Dendritic cells as therapeutic vaccines against cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Cancer immunotherapy by dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Building on dendritic cell subsets to improve cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Endocrine side effects induced by immune checkpoint inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Regulatory T cells: friend or foe in immunity to infection?

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Natural versus adaptive regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Regulatory T cells and Toll-like receptors in tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Transient T cell depletion causes regression of melanoma metastases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Foxp3 expression in human cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Myeloid-derived suppressor cells: linking inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Myeloid-derived suppressor cell heterogeneity and subset definition.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Improving cancer immunotherapy by targeting tumor-induced immune suppression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Therapeutic targeting of myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Altered macrophage differentiation and immune dysfunction in tumor development

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Macrophage polarization in tumour progression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription‐3 and nuclear factor‐kappa B in tumor cells and tumor‐associated macrophages

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Alternative activation of macrophages by IL-4 requires SHIP degradation.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Krüppel-like factor 4 regulates macrophage polarization

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Macrophage Expression of Hypoxia-Inducible Factor-1α Suppresses T-Cell Function and Promotes Tumor Progression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Cell surface signaling molecules in the control of immune responses: a tide model.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Advances in targeting cell surface signalling molecules for immune modulation

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

New checkpoint inhibitors ride the immunotherapy tsunami.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Up on the tightrope: natural killer cell activation and inhibition

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

TLR3 agonists and proinflammatory antitumor activities

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

TAMable tumor-associated macrophages in response to innate RNA sensing

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

21 January 2018

Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Regulatory T cells in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Clinical setbacks for toll-like receptor 9 agonists in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.432

31 March 2020

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38154151&oldid=2201331497"